Every Form 4 that Scribe Therapeutics Inc. (SCTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCTX filings page.
Scribe Therapeutics (SCTX) insider filings report that entities associated with Avoro Capital Advisors and Avoro Ventures indirectly purchased 2,391,238 shares of Common Stock. This includes 2,333,333 shares bought in the IPO at $15.00 per share and additional open‑market purchases at $22.31 and $18.25 per share on behalf of Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P. The shares are held by these funds, with the reporting persons potentially deemed beneficial owners through advisory and control roles and disclaiming beneficial ownership beyond their pecuniary interest. Total reported indirect holdings include 3,088,888 shares, of which 697,650 arose from the automatic conversion of Series B Preferred Stock into Common Stock upon the IPO closing.
Scribe Therapeutics, Inc. reported that President, CEO and Chairman Benjamin L. Oakes received three option awards for its common stock. On March 13, 2026, he was granted 12,969 options with a $19.13 exercise price, which are fully vested. On July 23, 2026, he received a time-based option for 264,784 shares at $15.00 per share, vesting in equal monthly installments over four years starting August 23, 2026, and a performance-based option for 429,599 shares at $15.00 per share, eligible to vest upon specified market-based performance criteria during a period from July 23, 2026 to July 23, 2029. The July 2026 grants expire on July 22, 2036, and the March 2026 grant expires on March 12, 2036.
Scribe Therapeutics, Inc. director James Dean Watson received a grant of stock options for 14,725 shares of Common Stock on July 23, 2026. These options have a conversion/exercise price of $15.00 per share and expire on July 22, 2036. Following this grant, he holds options for 14,725 shares directly.
The options will vest in three equal installments of one-third of the total shares on July 23, 2027, July 23, 2028, and July 23, 2029, subject to his continued service to Scribe Therapeutics on each vesting date.
Scribe Therapeutics, Inc. director Joshua Bleharski received a grant of stock options for 14,725 shares of common stock on July 23, 2026. The options have an exercise price of $15.00 per share and expire on July 22, 2036. They vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on continued service.
Scribe Therapeutics, Inc. Chief Financial Officer David Parrot reported multiple equity awards and open-market purchases. On July 23, 2026 he received stock options for 109,426 shares at $15.00 per share that vest monthly over four years, plus performance-based options for 109,426 shares at $15.00 that may vest between July 23, 2026 and July 23, 2029 based on market-based criteria. He also reported indirect open-market purchases of 1,333 common shares for a spouse and 1,333 shares for a child at $15.00 per share. A prior option grant for 8,909 shares at $19.13, fully vested and expiring March 12, 2036, was also disclosed under Rule 16a-2(a) in connection with the company’s initial public offering.
Scribe Therapeutics, Inc. reported that Dr. Behzad Aghazadeh and affiliated entities Avoro Capital Advisors LLC and Avoro Ventures LLC received a grant of 14,725 stock options to purchase Common Stock. The options carry a $15.00 exercise price and expire on July 22, 2036. They vest in three equal installments on July 23, 2027, July 23, 2028, and July 23, 2029, subject to Dr. Aghazadeh’s continued service. The reporting persons expressly disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.